Stem cells Queen Creek: joint soreness and treatment choices

Gentle daily movement often eases stiffness

Complete rest can leave a joint tighter. Use an easy walk or gentle motion that doesn't sharply raise the soreness. Stronger nearby muscles can share more of the work. If you're much worse the next morning, shorten the activity. Add a little time once the joint settles.

Pushing through sharp soreness won't earn you anything.

Warmth before moving may loosen stiffness. Cold after activity may calm swelling. A fitted brace or cane can make daily movement easier, though it can't explain the cause. Medicine isn't safe for every health history. Ask your regular clinician which kind, if any, fits you. Rest after a demanding day still matters, but long hours without movement may make your first steps harder.

Soreness that keeps returning is worth an exam

Arrange a visit when the ache limits sleep, walking, stairs, or getting dressed. Bring older records if you have them. The clinician will ask about your health and examine how the joint moves. Ask, “What do you think is making this joint sore?” Then ask how you'll know whether the chosen care is helping.

For soreness that won't settle, QC Kinetix offers regenerative treatments—non-surgical procedures using a product made after blood is drawn or marrow is taken. At its Chandler office, a medical provider, meaning the clinician doing your exam and procedure, puts that product inside your aching joint. The hoped-for result is easier movement with less soreness, but people respond differently. They'll tell you whether the option fits your joint and health. If it doesn't, ask whether home exercise, medicine, physical therapy, or a surgeon's visit makes more sense.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

3. The 2018 AAOS/NIH consensus work group recommended that minimally manipulated mixed cell preparations be called CELL THERAPY rather than stem cell therapy, and that their untested and uncharacterised nature be clearly communicated to patients and the public, because stem cells have properties these preparations do not meet.

   Chu CR, et al. — Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg, 2019. DOI: 10.5435/JAAOS-D-18-00305.

4. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

5. Global Burden of Disease data show osteoarthritis age-standardised prevalence rose 9.3 percent between 1990 and 2017 and years lived with disability rose 9.6 percent, with prevalence higher in women and rising with age.

   Safiri S, et al. — Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis, 2020. DOI: 10.1136/annrheumdis-2019-216515.